Trial Profile
Efficacy and safety of 12 weeks of ledipasvir (inhib- itor of HCV NS5A) plus sofosbuvir (HCV nucleotide-ana- logue NS5B polymerase inhibitor) in treatment-naïve and (peg)interferon ± ribavirin-experienced hepatitis C virus genotype 6 patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Nov 2017
Price :
$35
*
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 16 Nov 2017 New trial record
- 24 Oct 2017 Results presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases